TriangleDurvalumab (NCT03011814)
Durvalumab trial for Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma (NCT03011814). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for cutaneous or peripheral T cell lymphoma that has returned or not responded after at least two earlier systemic treatments.
The idea: restore the immune response against the lymphoma. Durvalumab is an antibody that blocks the PD-1 and PD-L1 checkpoint. Lenalidomide, an oral immune-modulating drug, may strengthen that effect.
In the phase 1 part, in cutaneous lymphoma, no dose-limiting toxicities were seen, and of 12 patients evaluable for response, 7 had partial responses. The phase 2 part randomizes patients to durvalumab alone or with lenalidomide. At City of Hope in Duarte, Christiane Querfeld leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.